GDPD6 mRNA levels were shown to be increased in metastasizing as compared to non-metastasizing endometrial carcinomas, and GDPD6 expression was negatively associated with relapse-free survival in endometrial and ovarian cancers (162). The gene discussed is GPCPD1; the disease is ovarian cancer.